Want to see IN:AUROPHARMA full AI Analyst Report?
AUROPHARMA Stock Chart & Stats
₹1207.35
-₹25.45(-1.99%)
At close: 4:00 PM EST
₹1207.35
-₹25.45(-1.99%)
Day’s Range― - ―
52-Week Range₹1,017.00 - ₹1,636.00
Previous CloseN/A
Volume696.31K
Average Volume (3M)40.80K
Market Cap
₹893.45B
Enterprise Value₹618.45K
Total Cash (Recent Filing)₹106.18B
Total Debt (Recent Filing)₹80.73B
Price to Earnings (P/E)25.7
Beta0.66
Next Earnings
Aug 06, 2026EPS Estimate
17.26Next Dividend Ex-DateN/A
Dividend Yield0.33%
Share Statistics
EPS (TTM)60.34
Shares Outstanding575,377,870
10 Day Avg. Volume31,329
30 Day Avg. Volume40,801
Financial Highlights & Ratios
PEG Ratio24.40
Price to Book (P/B)2.00
Price to Sales (P/S)2.25
P/FCF Ratio26.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)77.6
Revenue Forecast (FY)₹393.74B
Bulls Say, Bears Say
Bulls Say
Conservative LeverageA lower debt-to-equity (~0.21) and expanding equity base indicate a conservatively levered balance sheet. This reduces refinancing and solvency risk, preserves financial flexibility for capex, regulatory inspections, or opportunistic M&A, and supports durable operations through downturns.
Improving Cash GenerationA meaningful shift to positive free cash flow (~28.3B) and stronger operating cash flow improves internal funding capacity. Over months this supports reinvestment in capacity, remediation, and working capital without reliance on external debt, reducing long-term funding costs and execution risk.
Diversified Pharma ModelA dual stream of finished dosages and APIs plus exposure to regulated U.S./European markets provides scale and vertical integration. Internal API supply can lower costs and insulate production, while geographic diversification reduces reliance on any single market's pricing or regulatory cycle.
Bears Say
Margin CompressionA sharp fall in gross margin to ~39% signals sustained pricing pressure or cost increases in core generics/APIs. Lower gross margins materially reduce operating leverage and cash generation, constraining the company's ability to fund growth, maintain margins, or absorb regulatory remediation over the medium term.
Moderate, Falling ROEDeclining ROE near 9% suggests shareholder capital is producing only modest returns. Persistently moderate ROE can reflect competitive pressure, lower pricing power, or capital intensity, limiting long-term EPS growth and investor returns unless margins or asset efficiency improve materially.
Earnings Not Rising With RevenueRevenue gains that do not translate into higher net income indicate margin erosion or rising costs. Over months this signals issues in scalability or product mix, which can cap EPS growth and limit the firm's ability to convert top-line growth into durable shareholder value without efficiency gains.
Aurobindo Pharma Ltd News
AUROPHARMA FAQ
What was Aurobindo Pharma Ltd’s price range in the past 12 months?
Aurobindo Pharma Ltd lowest stock price was ₹1017.00 and its highest was ₹1636.00 in the past 12 months.
What is Aurobindo Pharma Ltd’s market cap?
Aurobindo Pharma Ltd’s market cap is ₹893.45B.
When is Aurobindo Pharma Ltd’s upcoming earnings report date?
Aurobindo Pharma Ltd’s upcoming earnings report date is Aug 06, 2026 which is in 21 days.
How were Aurobindo Pharma Ltd’s earnings last quarter?
Aurobindo Pharma Ltd released its earnings results on May 21, 2026. The company reported ₹15.86 earnings per share for the quarter, missing the consensus estimate of ₹16.331 by -₹0.471.
Is Aurobindo Pharma Ltd overvalued?
According to Wall Street analysts Aurobindo Pharma Ltd’s price is currently Overvalued.
Does Aurobindo Pharma Ltd pay dividends?
Aurobindo Pharma Ltd pays a Annually dividend of ₹4 which represents an annual dividend yield of 0.33%. See more information on Aurobindo Pharma Ltd dividends here
What is Aurobindo Pharma Ltd’s EPS estimate?
Aurobindo Pharma Ltd’s EPS estimate is 17.26.
How many shares outstanding does Aurobindo Pharma Ltd have?
Aurobindo Pharma Ltd has 575,377,870 shares outstanding.
What happened to Aurobindo Pharma Ltd’s price movement after its last earnings report?
Aurobindo Pharma Ltd reported an EPS of ₹15.86 in its last earnings report, missing expectations of ₹16.331. Following the earnings report the stock price went up 1.881%.
Which hedge fund is a major shareholder of Aurobindo Pharma Ltd?
Currently, no hedge funds are holding shares in IN:AUROPHARMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aurobindo Pharma Ltd
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and API space for sterile and non-sterile penicillin’s, cephalosporins, penems, and non-beta lactams. The company has operations in India, the United States, Europe, Puerto Rico, and internationally. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
Technical Analysis
Alkem Laboratories Ltd.
―
Glenmark Pharmaceuticals Limited
―
Laurus Labs Ltd.
―
Lupin Limited
―
Zydus Lifesciences Limited
―